Given their high target specificity and limited toxicity compared to small molecule drugs, biotherapeutics have revolutionized treatment paradigms across a myriad of clinical conditions, including metabolic disorders, cancers, neurological disorders and autoimmune disorders. In fact, the extent of growth of such therapies can be gauged from the fact that more than 300 biopharmaceuticals have been approved between 2002 and 2018. Such products are inherently complex, and their full potential continues to remain untapped owing to an array of concerns associated with their development, manufacturing and administration. This is where novel drug delivery technologies come in and save the day!
Presently, over 80 novel drug delivery technologies, with the potential to significantly improve drug properties and / or therapy adherence to various target drug classes, are under development
Proteins and peptides represent the dominant class of therapeutics using such drug delivery technologies; although a number of novel delivery strategies are available, the parenteral route continues to be the preferred mode of delivery
Several stakeholders are engaged in the development of advanced technology platforms, capable of improving drug release properties and exploiting different invasive and non-invasive dosing strategies
The US is currently considered to be the base of operations for majority of the companies in this market, featuring a favorable research environment and a healthy mix of novice and well-established players
In order to achieve a competitive edge, drug delivery technologies developers are increasingly focusing on integration of advanced features in their respective platforms and affiliated offerings
Over the years, more than 2,000 patents have been granted / filed related to novel technologies for biologics, demonstrating continued efforts towards innovation in this domain
The increasing instances of partnerships showcase the rising interest in this domain; companies are actively collaborating to develop biologics with unique delivery mechanisms
Short term opportunity in the drug delivery technologies market is likely to be driven by licensing activity and will depend on the capability of novel technologies to meet unmet drug delivery needs
The major share is anticipated to remain within the developed regions, while the long term opportunity is likely to be driven by expansion into diverse therapeutic areas and exploiting different routes of delivery
To learn more, please click here. For any queries / suggestions, please do not hesitate to contact us at email@example.com. You can also download the SAMPLE REPORT on delivery technologies by Roots Analysis.
Arun is an enthusiastic professional and has been associated with Roots Analysis since the very early years. He has led multifaceted roles over the years be it business research, consulting, competitive intelligence, IT & technology, sales and marketing. He currently drives strategic thinking and execution within the sales and marketing domain. With educational background in life sciences from Thapar University and digital marketing credentials from Indian School of Business, he has led a lot of critical initiatives at the organization. His background in life sciences has been one of the key reasons for quick understanding and implementation of customized marketing strategies. During his early years, he has led multiple consulting assignments for global clients ranging from competitive landscaping, deal structuring and preparing go-to-market strategy for his clients.